Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
REFI
4001
Chicago Atlantic Real Estate Finance
REFI
$268M
| $349K | ﹤0.01% |
28,486
+2,916
| +11% | +$37.2K |
|
|
CEPO
4002
Cantor Equity Partners I
CEPO
$272M
| $349K | ﹤0.01% |
+33,533
| New | +$351K |
|
|
BLFY
4003
DELISTED
Blue Foundry Bancorp
BLFY
| $348K | ﹤0.01% |
28,027
+1,549
| +6% | +$15.5K |
|
4004
Tonix Pharmaceuticals
TNXP
$205M
| $347K | ﹤0.01% |
22,231
+9,765
| +78% | +$180K |
|
|
SNWV
4005
SANUWAVE Health Inc
SNWV
$46.2M
| $346K | ﹤0.01% |
11,610
+1,306
| +13% | +$41.9K |
|
4006
Palladyne AI
PDYN
$313M
| $346K | ﹤0.01% |
81,226
+47,300
| +139% | +$318K |
|
4007
3D Systems Corp
DDD
$603M
| $346K | ﹤0.01% |
195,334
-163
| -0.1% | -$397 |
|
4008
Stereotaxis
STXS
$139M
| $346K | ﹤0.01% |
150,246
+7,062
| +5% | +$18.8K |
|
4009
Perion Network
PERI
$377M
| $345K | ﹤0.01% |
36,033
+25,483
| +242% | +$247K |
|
|
TBCH
4010
Turtle Beach Corp
TBCH
$230M
| $344K | ﹤0.01% |
24,511
+3,393
| +16% | +$50.5K |
|
|
TBRG
4011
DELISTED
TruBridge
TBRG
| $344K | ﹤0.01% |
15,570
+1,149
| +8% | +$24.1K |
|
4012
Opendoor
OPEN
$3.39B
| $344K | ﹤0.01% |
58,940
+9,885
| +20% | +$70.8K |
|
4013
Falcon's Beyond
FBYD
$490M
| $343K | ﹤0.01% |
+22,864
| New | +$316K |
|
4014
Certara
CERT
$1.22B
| $342K | ﹤0.01% |
38,816
+8,712
| +29% | +$89.7K |
|
4015
Foghorn Therapeutics
FHTX
$394M
| $341K | ﹤0.01% |
63,190
+4,704
| +8% | +$21.3K |
|
4016
Hagerty
HGTY
$1.3B
| $340K | ﹤0.01% |
25,333
-4
| -0% | -$50 |
|
4017
Nkarta
NKTX
$171M
| $340K | ﹤0.01% |
183,923
+39,776
| +28% | +$79.5K |
|
4018
Perma-Fix Environmental Services
PESI
$412M
| $340K | ﹤0.01% |
26,981
+2,612
| +11% | +$33.3K |
|
|
CHYM
4019
Chime Financial
CHYM
$12B
| $338K | ﹤0.01% |
+13,437
| New | +$285K |
|
|
FSFG
4020
DELISTED
First Savings Financial Group
FSFG
| $338K | ﹤0.01% |
10,607
+831
| +9% | +$25.8K |
|
4021
PUT
SentinelOne
S
$7.64B
| $338K | ﹤0.01% |
22,500
| – | – |
|
|
USAS
4022
Americas Gold and Silver
USAS
$1.75B
| $337K | ﹤0.01% |
65,874
+53,714
| +442% | +$242K |
|
4023
OptimizeRx
OPRX
$132M
| $336K | ﹤0.01% |
27,441
+4,317
| +19% | +$70.5K |
|
4024
iShares Global Consumer Staples ETF
KXI
$1.06B
| $336K | ﹤0.01% |
5,200
| – | – |
|
4025
eHealth
EHTH
$39.7M
| $336K | ﹤0.01% |
72,950
+4,370
| +6% | +$19.3K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.